EFTX-G12V: a novel KRAS^G12V-selective RNAi therapeutic

Area of Science:

• Oncology
• Molecular Biology
• RNA Therapeutics

Background:

• KRAS^G12V mutations drive numerous cancers, presenting significant therapeutic challenges.
• Targeting KRAS^G12V has historically been difficult, leaving a critical unmet need in precision oncology.

Purpose of the Study:

• To develop and evaluate EFTX-G12V, a novel RNA interference (RNAi) therapeutic agent.
• To assess the efficacy of EFTX-G12V in silencing KRAS^G12V and inducing tumor regression.

Main Methods:

• Development of GE11-conjugated small interfering RNA (siRNA) named EFTX-G12V.
• Administration of EFTX-G12V to target KRAS^G12V-driven tumors.
• Evaluation of tumor regression, oncogenic signaling inhibition, angiogenesis modulation, and anti-tumor immunity enhancement.

Main Results:

• EFTX-G12V selectively silenced the KRAS^G12V oncogene.
• Treatment with EFTX-G12V resulted in significant tumor regression.
• The therapy demonstrated inhibition of oncogenic signaling and angiogenesis.
• EFTX-G12V enhanced the anti-tumor immune response.

Conclusions:

• EFTX-G12V is a promising RNAi-based precision oncology strategy.
• This approach offers a potential therapeutic option for cancers driven by KRAS^G12V mutations.
• EFTX-G12V represents a breakthrough for previously undruggable oncogenic mutations.